On 6 August 2020, US President Donald Trump signed an executive order, dubbed ‘Buy American’, with the aim of increasing the production of essential medicines in the US for domestic use. Here, Victoria Rees discusses the order and what it means for drug manufacturers in the US and rest of the world.
SOARING DRUG prices in the US have been a controversial issue for many years and with the costs of healthcare under the spotlight due to the COVID-19 pandemic, the American government is under pressure to find a solution. One potential approach to bring down the price of medicines is outlined in the ‘Buy American’ executive order signed by President Trump. The order is intended to hit two birds with one stone: boost American essential drug manufacturing, thereby strengthening the pharma supply chain for Americans and reduce costs for patients in the US.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
As a reaction to the outbreak of COVID-19 and other potential health threats, the order outlines that the US must reduce the country’s “dependence on foreign manufacturers for essential medicines, medical countermeasures and critical inputs,”1 to ensure that the country can be a self-sustaining nation regarding basic healthcare.
However, with only the beginnings of the work outlined in the executive order underway, it remains to be seen whether it will work as intended and come to fruition.
The executive order – intentions and goals
The four main aims of the executive order are to increase the development of domestic medicine production, ensure long-term demand for said medicines, maximise production capabilities and combat counterfeit medicines.1 With a robust manufacturing network and distribution vulnerabilities identified and mitigated, the US should, in theory, have a resilient supply chain for essential medicines.
Although the executive order is meant to increase the production of essential medicines in the US, this is a list yet to be determined by the US Food and Drug Administration (FDA) Commissioner.1 Essential medicines and their ingredients are defined as those that “are medically necessary to have available at all times in an amount adequate to serve patient needs and in the appropriate dosage forms.” Also, for the drug to be considered “made in the US”, its ingredients must be produced or the finished drug product/device must be manufactured, prepared, propagated, compounded or processed in the US.1
Once this list is confirmed, the order will enable the US Department of Health and Human Services (HHS) to utilise a law from 1950 to buy the medicines classed as “essential” from pharmaceutical companies in the US.2 The Secretary of HHS will prioritise US federal government contracts or orders for essential medicines, medical countermeasures or critical inputs over other contracts or orders. The Secretary shall also allocate the materials, services and facilities deemed necessary or appropriate to promote the manufacture of these products.1
The order further directs the FDA and US Environmental Protection Agency to prioritise domestic pharmaceutical ingredient manufacturers during regulatory review, giving them a significant advantage over international companies.3
Lastly, the order commits to combat the distribution of counterfeit medicines on ecommerce platforms and third-party online sellers involved in the government procurement process.1
All in all, the goals of the order are noble; but what would be the reality of their coming into force and impacting pharmaceutical supply chains?
Impact on US manufacturers
Within 90 days of this executive order – on 4 November 2020 – each department and agency involved in the procurement of essential medicines, in consultation with the FDA Commissioner, is required to develop and implement procurement strategies.1
With a robust manufacturing network and distribution vulnerabilities identified and mitigated, the US should, in theory, have a resilient supply chain for essential medicines”
These include long-term contracts between at least two manufacturers, which will ensure competition and further reduction of medicine costs. To aid drug or ingredient manufacturers, guidance documents are to be streamlined to provide for the development of advanced production facilities.1
Furthermore, following the identification of essential medicines by the FDA Commissioner, the US Trade Representative is then required to modify federal procurement product coverage under applicable Free Trade Agreements and the World Trade Organization Agreement on Government Procurement to exclude coverage of essential medicines. This means that essential medicines made outside the US may no longer be procured by its government and domestic manufacturers will consequently be engaged. According to the order, federal procurement may also be further altered as the FDA Commissioner sees fit.1
To then expediate the process of getting essential medicines to patients, the order outlines that the FDA can accelerate approval or clearance of US producers of essential medicines, helping manufacturers to swiftly make a profit on their drugs sold to the government.
Despite the proposed benefits of this executive order, critics argue it will only cause disruption to pharmaceutical businesses and divert vital resources away from the effort to develop COVID-19 vaccines and treatments. In an open letter published by the US Chamber of Commerce, representatives from national, state and local organisations stress that the US does not produce all of the raw materials or intermediate goods that are required for drug development or production of the medical equipment needed to combat the COVID-19 pandemic.4 They say that although the order is intended to help US patients during the pandemic, it will be counterproductive and could instead cause medicine shortages.
After the procurement of medicines, the order instructs the US government machinery to improve and streamline the supply chain for essential medicines”
In another open letter to President Trump, pharmaceutical and health organisations write: “Proposals to drive all manufacturing to the US not only overestimate the potential feasibility and underestimate the time and effort it would take to make such changes, but also misunderstand that a diverse pharmaceutical supply chain is precisely what enables the industry to respond quickly and make adjustments in its supply chain sourcing during natural emergencies and global public health crises.”5
While the order will attempt to engage US manufacturers and reduce the impacts of COVID-19 on the US population, it is likely that this will have further implications. As a result, pharmaceutical manufacturers will be under high pressure to make treatments and vaccines for COVID-19, produce increased levels of essential medicines or their ingredients and update their processes to accommodate for this.
The global picture: supply chains
After the procurement of medicines, the order instructs the US government machinery to improve and streamline the supply chain for essential medicines. By 2 February 2021, the Secretary of HHS must identify vulnerabilities in the US medicine logistics network.1 Any weaknesses must then be mitigated, including reviewing FDA regulations to determine whether any of those regulations may be a barrier to domestic production of essential medicines or recommending any changes to applicable law to President Trump.1
However, the opponents of the order have emphasised that altering the logistics network within the US will cause disruptions to the supply chain in the rest of the world. Pharmaceutical Research and Manufacturers of America (PhRMA) President and Chief Executive Officer, Stephen Ubl, said in a statement: “The ‘Buy American’ executive order could disrupt the global pharmaceutical supply chain, jeopardising our ability to respond to the current crisis and potentially leading to major long-term supply chain disruptions, including shortages. Rather than government mandates, we should look for policies that enable more domestic manufacturing without putting the stability of pharmaceutical supply chains at risk.”6
Others have pointed out that this will not just negatively impact the rest of the world – it could leave American patients with medicine shortages. In the US, one in every three pills consumed is produced by an India generics manufacturer.7 Dr Amesh Adalja, a Senior Scholar of Johns Hopkins Center for Health Security, US, said: “While it is important, especially when it comes to pandemic preparedness, to have secure supply chains it does not mean that supply chains must be all domestic.”
The order outlines that the FDA can accelerate approval or clearance of US producers of essential medicines, helping manufacturers to swiftly make a profit on their drugs sold to the government”
Although it seems the flow of medicines from the rest of the world to the US will cease, this is not entirely the case. Despite the agencies in the US being granted the ability to refuse imports of essential medicines if the facilities in which they are produced refuse or unreasonably delay an inspection,1 there are ways that companies may still deliver their drugs to the country.
Firstly, medicines that are not classed as essential will be excluded from any regulatory changes and others may be able to work through several loopholes in the order. One of these is that if medicines classed as essential are not made in sufficient or reasonably available commercial quantities in the US, then they are to be imported. Furthermore, if a public health emergency occurs, the order says the required medicines can be imported.1
Will the executive order come into force?
With 72 percent of manufacturers that supply pharmaceutical ingredients to the US being located overseas, including 13 percent in China,2 it is clear that if the executive order comes into full force it could overhaul the US pharmaceutical supply chain, whether with positive or negative impacts.
However, with the timeframe of the executive order instructions set in stone it leaves little room for flexibility, a potential misstep with the upcoming election. If Trump fails to retain his position, it could see his rival Joe Biden reversing his efforts to strengthen US manufacturing of essential medicines. Only in November will the US decide if Trump’s efforts to provide a stable supply chain are enough to let him see his plans through.
About the author
Victoria Rees is the Junior Editor for European Pharmaceutical Review and Drug Target Review.
References
Executive Order on Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States | The White House [Internet]. The White House. 2020 [cited 2 October 2020]. Available from: https://www.whitehouse.gov…
Collins M., Trump signs order in Ohio requiring government to buy ‘essential’ drugs from US companies [Internet]. Usatoday.com. 2020 [cited 2 October 2020]. Available from: https://www.usatoday.com…
Reuters Staff. Trump executive order to boost U.S. drug manufacturing -Navarro [Internet]. U.K. 2020 [cited 2 October 2020]. Available from: https://uk.reuters.com/article/idUKL1N2F80KE
PhRMA Statement on the “Buy American” Executive Order [Internet]. Phrma.org. 2020 [cited 2 October 2020]. Available from: https://phrma.org/Press-Release…
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.